#### **BIO IMAGING TECHNOLOGIES INC**

(a)( )

Form SC 13G January 19, 2006

```
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(Under the Securities Exchange Act of 1934)
(Amendment No. 1) *
Bio-Imaging Technologies Inc.
(Name of Issuer)
COMMON STOCK
_____
(Title of Class of Securities)
09056N103
(Cusip Number)
December 31, 2005
(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant
to which this schedule is filed:
[X] Rule 13d-1 (b)
[ ] Rule 13d-1 (c)
[ ] Rule 13d-1 (d)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing of this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in
a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act, but shall be subject to all
other provisions of the Act (however, see the Notes.)
[Continued on the following page(s)]
Page 1 of 4 Pages
CUSIP No 09056N103
                                Page 2 of 4 Pages
   Name of reporting person
       S.S. or I.R.S. identification no. of above person
       Babson Capital Management LLC
       51-0504477
2. Check the appropriate box if a member of a group
```

3.		
	SEC use only	
4.	Citizenship or place of o: Delaware	rganization
	5	. Sole Voting Power
		605,400
		hared Voting Power
	beneficially owned by	0
	each Reporting 7	. Sole Dispositive Power
	person with	605,400
3.	Shared Dispositive Power 0	
€.	Aggregate amount beneficia	ally owned by each reporting person
	605,400	
0.		ount in row (9) excludes certain shares*
11.	Percent of class represent 5.43%	
12.	Type of Reporting person	
	IA	
Page (	IA 3 of 4 Pages	Cusip #: 09056N103
	3 of 4 Pages	Cusip #: 09056N103
SCHEDU	3 of 4 Pages ULE 13G	Cusip #: 09056N103
SCHEDU	3 of 4 Pages	Cusip #: 09056N103
SCHEDU	3 of 4 Pages ULE 13G	Cusip #: 09056N103
SCHEDU ITEM 1 Bio-1	3 of 4 Pages ULE 13G 1(A): NAME OF ISSUER:	
SCHEDU ITEM 1 Bio-1	3 of 4 Pages  ULE 13G  1(A): NAME OF ISSUER:  Imaging Technologies Inc.	
SCHEDU ITEM 1 Bio-1 1(B):	3 of 4 Pages  ULE 13G  1(A): NAME OF ISSUER:  Imaging Technologies Inc.  ADDRESS OF ISSUER'S PRINCIPATION AND A PAGE AND	PAL EXECUTIVE OFFICES:
SCHEDU ITEM 1 Bio-1 1(B):	3 of 4 Pages  ULE 13G  1(A): NAME OF ISSUER:  Imaging Technologies Inc.  ADDRESS OF ISSUER'S PRINCIPATE STATE AND ADDRESS OF ISSUER'S PRINCIPATE STATE STATE AND ADDRESS OF ISSUER'S PRINCIPATE STATE AND ADDRESS OF ISSUER'S PRINCIPATE STATE AND ADDRESS OF ISSUER'S PRINCIPATE STATE STATE AND ADDRESS OF ISSUER'S PRINCIPATE STATE	PAL EXECUTIVE OFFICES:
SCHEDUITEM 1 Bio-1 1(B):	3 of 4 Pages  ULE 13G  1(A): NAME OF ISSUER:  Imaging Technologies Inc.  ADDRESS OF ISSUER'S PRINCIP  826 Newton-Yardley Road Newtown, PA 18940-1721  2(A): NAME OF PERSON FILING	PAL EXECUTIVE OFFICES:
SCHEDUITEM : Bio-: 1(B):	3 of 4 Pages  ULE 13G  1(A): NAME OF ISSUER:  Imaging Technologies Inc.  ADDRESS OF ISSUER'S PRINCIP  826 Newton-Yardley Road Newtown, PA 18940-1721  2(A): NAME OF PERSON FILING	PAL EXECUTIVE OFFICES:  : LLC (Babson Capital)

470 Atlantic Avenue Boston, MA 02210-2208

2

ITEM 2(C): CITIZENSHIP:

See Item 4 of Cover Page

ITEM 2(D): TITLE OF CLASS OF SECURITIES:

See Cover Page

ITEM 2(E): CUSIP NUMBER:

See Cover Page

ITEM 3: TYPE OF REPORTING PERSON:

If this statement is filed pursuant to Sections 240.13d-1 (b) or 240.13d-2 (b) or (c), check whether the filing person is a:

ITEM 4: OWNERSHIP:

(a) AMOUNT BENEFICIALLY OWNED: Babson Capital, in its capacity as investment adviser, may be deemed the beneficial owner of 605,400 shares of common stock of the Issuer which are owned by investment advisory client(s).

(b) PERCENT OF CLASS: 5.43%

(c) For information on voting and dispositive power with respect to the above listed shares, see Items 5-8 of Cover Page.

Page 4 of 4 Pages Cusip #: 09056N103

ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

Not Applicable

ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Not Applicable

ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY:

Not Applicable

ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: Not Applicable

ITEM 9: NOTICE OF DISSOLUTION OF GROUP:

Not Applicable

ITEM 10: CERTIFICATION:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the

ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

#### SIGNATURE:

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 13, 2006

Signature: // Robert J. Guerin //
Name/Title: ROBERT J. GUERIN

Senior Compliance Officer

January 13, 2006

Securities and Exchange Commission Operations Center Attn: Stop 0-7 6432 General Green Way Alexandria, VA 22312-2413

Re: SCHEDULE 13G ON BEHALF OF BIO-IMAGING TECHNOLOGIES, INC. FOR THE YEAR ENDING DECEMBER 31, 2005

Dear Sir or Madam:

Babson Capital Management LLC is filing today an amendment to Schedule 13G through the EDGAR system as required by Section 240.13d-1(b) to reflect a change in beneficial ownership of the outstanding stock of the above-mentioned issuer.

Please note that the shares as to which this Schedule is filed are owned by various investment advisery clients of Babson Capital, which may be deemed a beneficial owner of the shares only by virtue of the direct or indirect investment discretion it possesses pursuant to the provisions of investment advisory agreements with such clients.

A copy of the Schedule 13G is being sent to the issuer as required by Rule 13d-7.

Comments or questions concerning the above may be directed to the undersigned at (617) 761-3779.

Sincerely,

```
// Robert J. Guerin //
ROBERT J. GUERIN
Senior Compliance Officer
```